The coronavirus vaccine developed by AstraZeneca (NASDAQ: AZN) in partnership with Oxford University has succeeded in preventing transmission of COVID-19. Unfortunately, a disappointing series of ...

People who receive AstraZeneca’s COVID-19 vaccine have a slightly increased risk of bleeding problems, according to a study published June 9 in Nature Medicine. Researchers observed adults in Scotland ...

Rare but dangerous blood clotting associated with that vaccine as well as AstraZeneca’s had a genetic cause, according to a new paper.

Researchers identify genetic mutation in small group of people who developed the serious disorder after receiving the AstraZeneca or Johnson & Johnson vaccine.

The U.S. Food and Drug Administration (FDA) said the safety risks associated with Andexxa now outweigh its benefits, prompting AstraZeneca Plc (NASDAQ: AZN) to seek a voluntary withdrawal of the ...